NO323562B1 - Immunstimulerende og metastasehemmende fermentert torket materiale, fremstilling og anvendelser derav samt kosttilskudd og farmasoytisk produkt. - Google Patents
Immunstimulerende og metastasehemmende fermentert torket materiale, fremstilling og anvendelser derav samt kosttilskudd og farmasoytisk produkt. Download PDFInfo
- Publication number
- NO323562B1 NO323562B1 NO20000675A NO20000675A NO323562B1 NO 323562 B1 NO323562 B1 NO 323562B1 NO 20000675 A NO20000675 A NO 20000675A NO 20000675 A NO20000675 A NO 20000675A NO 323562 B1 NO323562 B1 NO 323562B1
- Authority
- NO
- Norway
- Prior art keywords
- fermented
- dried material
- fermentation
- wheat germ
- dried
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 63
- 206010027476 Metastases Diseases 0.000 title claims abstract description 27
- 230000009401 metastasis Effects 0.000 title claims abstract description 21
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 16
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 2
- 229940127557 pharmaceutical product Drugs 0.000 title claims 2
- 241000209140 Triticum Species 0.000 claims abstract description 27
- 235000021307 Triticum Nutrition 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 238000000855 fermentation Methods 0.000 claims abstract description 23
- 230000004151 fermentation Effects 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000012736 aqueous medium Substances 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 5
- OLBNOBQOQZRLMP-UHFFFAOYSA-N 2,6-dimethoxy-p-benzoquinone Chemical compound COC1=CC(=O)C=C(OC)C1=O OLBNOBQOQZRLMP-UHFFFAOYSA-N 0.000 claims description 42
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000005913 Maltodextrin Substances 0.000 claims description 13
- 229920002774 Maltodextrin Polymers 0.000 claims description 13
- 229940035034 maltodextrin Drugs 0.000 claims description 13
- ZJKWJHONFFKJHG-UHFFFAOYSA-N 2-Methoxy-1,4-benzoquinone Chemical compound COC1=CC(=O)C=CC1=O ZJKWJHONFFKJHG-UHFFFAOYSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 24
- 239000000203 mixture Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 238000011835 investigation Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000005418 vegetable material Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 206010027457 Metastases to liver Diseases 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 150000004054 benzoquinones Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 238000010911 splenectomy Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- -1 methoxy-substituted p-benzoquinones Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000019362 perlite Nutrition 0.000 description 2
- 239000010451 perlite Substances 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 150000004059 quinone derivatives Chemical class 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003210 sulforhodamine B staining Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 125000000695 menaquinone group Chemical group 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- MHIGBKBJSQVXNH-IWVLMIASSA-N methacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/20—Malt products
- A23L7/25—Fermentation of cereal malt or of cereal by malting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
- Grain Derivatives (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9701392A HUP9701392D0 (en) | 1997-08-13 | 1997-08-13 | Immunostimulating and methastasis-inhibiting plant extract, pharmaceutical compositions containing thereof, process for production of plant extract and use for production of immunostimulating and metastasis-inhibiting pharmaceutical composition thereof |
| HU9801797A HU223344B1 (hu) | 1997-08-13 | 1998-08-05 | Immunstimuláns és metasztázist gátló fermentált, szárított anyag, ezt tartalmazó gyógyszerkészítmények, eljárás az előállítására és alkalmazásai |
| PCT/HU1998/000077 WO1999008694A1 (en) | 1997-08-13 | 1998-08-11 | Immunostimulatory and metastasis inhibiting fermented vegetal material |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000675D0 NO20000675D0 (no) | 2000-02-10 |
| NO20000675L NO20000675L (no) | 2000-03-30 |
| NO323562B1 true NO323562B1 (no) | 2007-06-11 |
Family
ID=90014226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000675A NO323562B1 (no) | 1997-08-13 | 2000-02-10 | Immunstimulerende og metastasehemmende fermentert torket materiale, fremstilling og anvendelser derav samt kosttilskudd og farmasoytisk produkt. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6355474B1 (pt) |
| EP (1) | EP1003536B1 (pt) |
| JP (3) | JP4387586B2 (pt) |
| KR (2) | KR100544376B1 (pt) |
| CN (1) | CN1192099C (pt) |
| AT (1) | ATE227580T1 (pt) |
| AU (1) | AU754815B2 (pt) |
| BG (1) | BG64038B1 (pt) |
| BR (1) | BR9811936B1 (pt) |
| CA (1) | CA2300208C (pt) |
| CZ (1) | CZ298654B6 (pt) |
| DE (1) | DE69809434T2 (pt) |
| DK (1) | DK1003536T3 (pt) |
| EA (1) | EA003090B1 (pt) |
| EE (1) | EE04222B1 (pt) |
| ES (1) | ES2186208T3 (pt) |
| GE (1) | GEP20032988B (pt) |
| HK (1) | HK1033097A1 (pt) |
| HU (1) | HU223344B1 (pt) |
| ID (1) | ID25515A (pt) |
| IL (1) | IL134493A (pt) |
| ME (1) | ME00638B (pt) |
| NO (1) | NO323562B1 (pt) |
| PL (1) | PL191414B1 (pt) |
| PT (1) | PT1003536E (pt) |
| RS (1) | RS49692B (pt) |
| SK (2) | SK1822000A3 (pt) |
| TR (1) | TR200000404T2 (pt) |
| UA (1) | UA67747C2 (pt) |
| WO (1) | WO1999008694A1 (pt) |
| YU (1) | YU7200A (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534568B1 (en) | 1998-04-24 | 2003-03-18 | Crompton Corporation | Powder coating or adhesives employing silanes or silane treated fillers |
| FR2815822B1 (fr) * | 2000-10-30 | 2004-08-27 | Roquette Freres | Additif carbone pour fermentations alimentaires et compositions alimentaires le contenant |
| FR2834718B1 (fr) * | 2002-01-15 | 2004-12-24 | Cognis France Sa | Substances actives cosmetiques et/ou pharmaceutiques |
| ATE537836T1 (de) * | 2002-05-02 | 2012-01-15 | E L Management Corp | Verfahren zur verbesserung der biologischen aktivität von pflanzenextrakten |
| HUP0202638A3 (en) * | 2002-08-09 | 2007-08-28 | Hidvegi Mate Dr | Use of fermented wheat-germ extract for preparation of antiphlogistic compositions |
| EA009025B1 (ru) * | 2002-08-13 | 2007-10-26 | Мате Хидвеги | Применение ферментированного экстракта зародышей пшеницы в кормлении животных |
| EA009170B1 (ru) * | 2002-08-13 | 2007-10-26 | Мате Хидвеги | Применение ферментированных зародышей пшеницы в ветеринарной практике |
| WO2007140277A1 (en) | 2006-05-24 | 2007-12-06 | Vitality Concepts Corporation | Method for embedding and targeted release of micronutrients in activated dietary fibers |
| US7365102B1 (en) | 2007-02-26 | 2008-04-29 | Delphi Technologies, Inc. | Process for pre-reforming hydrocarbon fuels |
| HUP0900614A2 (en) * | 2009-09-29 | 2011-05-30 | Mate Dr Hidvegi | Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production |
| EP2403513A2 (en) * | 2009-03-06 | 2012-01-11 | Maté Hidvégi | Fractions of wheat germ ferment |
| US20130122580A1 (en) * | 2010-01-08 | 2013-05-16 | Sumitomo Bakelite Co., Ltd. | Culture vessel for forming aggregated cell mass |
| US20120164132A1 (en) * | 2010-08-02 | 2012-06-28 | Mate Hidvegi | Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses |
| GB201108560D0 (en) | 2011-05-20 | 2011-07-06 | 3 Ch Ltd | Use of fermented wheat germ in the treatment of inflammatory bowel disease |
| GB201110746D0 (en) * | 2011-06-23 | 2011-08-10 | Biropharma Uk Ltd | Wheat germ derived material |
| US11090353B2 (en) | 2013-04-22 | 2021-08-17 | David Wales | Gluten-free grain-concentrate substitute for fermented wheat germ drug product and method preparation |
| US11129389B2 (en) | 2013-04-22 | 2021-09-28 | David Wales | Gluten-free grain-concentrate substitute for fermented wheat germ food product and method of preparation |
| JP2017033691A (ja) * | 2015-07-30 | 2017-02-09 | 三菱自動車工業株式会社 | 車載電池パック、リチウムイオン補充装置、及びリチウムイオン補充方法 |
| CN107455551A (zh) * | 2016-06-06 | 2017-12-12 | 铜陵安尔生物科技有限公司 | 麦胚发酵黄酮提取物及其制备方法与在动物饲养中的应用 |
| JP6739774B2 (ja) | 2018-06-25 | 2020-08-12 | 学校法人立命館 | がんの治療、予防、改善、抑制又は転移抑制用組成物 |
| EP3659444B1 (en) | 2018-11-27 | 2023-12-06 | Gyula Bencze | Gluten-free grain-concentrate substitute for fermented wheat germ food product and method of preparation |
| WO2022091075A1 (en) * | 2020-11-01 | 2022-05-05 | Aili Life Sciences Ltd. | Combination compositions of probiotics with fermented wheat germ extract and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63230774A (ja) * | 1987-03-19 | 1988-09-27 | Seinosuke Ueda | 紫青系色素の製法 |
| JP2618286B2 (ja) * | 1990-10-25 | 1997-06-11 | 免疫代謝薬製造株式会社 | 降圧酵母製剤及びその製造法 |
| KR940001544B1 (ko) * | 1990-11-21 | 1994-02-24 | 강권중 | 은행잎을 위시한 천연약재로부터 미생물의 공서배양에 의한 건강식품의 제조방법 |
| JP3296433B2 (ja) * | 1990-11-30 | 2002-07-02 | 日本食品化工株式会社 | 酒類の製造法 |
| US5231017A (en) | 1991-05-17 | 1993-07-27 | Solvay Enzymes, Inc. | Process for producing ethanol |
| CA2129653C (en) * | 1992-02-06 | 1996-08-06 | James Allan Doncheck | Process for preparing a concentrated beer flavor product |
| CZ285508B6 (cs) * | 1993-08-09 | 1999-08-11 | Edward Baral | Použití trifenylethylenových antiestrogenů pro zvyšování citlivosti rakovinných buněk k lyzi zprostředkované zabíječskými buňkami |
| JPH07155136A (ja) * | 1993-12-03 | 1995-06-20 | Nippon Mektron Ltd | 植物発酵エキス粉末の製造方法 |
| PT659344E (pt) * | 1993-12-24 | 2001-12-28 | Dsm Nv | Composicoes de levedura seca traducao |
| ATE205055T1 (de) * | 1994-01-06 | 2001-09-15 | Hyd Kutato Fejleszto Ktf | Nahrungsmittel zur verhinderung der entwicklung von erkrankungen und verfahren zur herstellung dieser nahrungsmittel |
| JP3471879B2 (ja) * | 1994-01-20 | 2003-12-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | セリンキナーゼ活性の抑制方法、ｐｉ３−キナーゼのサブユニット間の結合活性の調整方法、ｐｉ３−キナーゼのサブユニット結合抗体、この抗体を生成するハイブリドーマ細胞系、核酸分子、プラスミド、アゴニスト、アンタゴニスト、ｐｉ３−キナーゼ活性を抑制するサブユニット結合分子、サブユニットの存在検出方法、ｐｉ３−キナーゼ活性の抑制剤製造方法、およびｐｉ３−キナーゼ活性の抑制剤 |
| JP2875739B2 (ja) * | 1994-04-27 | 1999-03-31 | エーザイ株式会社 | ＮＦκＢ活性阻害剤 |
| DK0684306T4 (da) * | 1994-05-27 | 2004-05-10 | Agrano Ag | Fremgangsmåde til fremstilling af en biomasse ud fra et kornsubstrat, anvendelse af de ved fremgangsmåden opnåede produkter, samt brödbagningsgærstof |
| JP4167733B2 (ja) * | 1996-12-16 | 2008-10-22 | 花王株式会社 | ＮＦ−κＢ活性化抑制剤 |
-
1998
- 1998-08-05 HU HU9801797A patent/HU223344B1/hu active IP Right Grant
- 1998-08-11 EP EP98940483A patent/EP1003536B1/en not_active Expired - Lifetime
- 1998-08-11 KR KR1020007001459A patent/KR100544376B1/ko not_active IP Right Cessation
- 1998-08-11 GE GEAP19985247A patent/GEP20032988B/en unknown
- 1998-08-11 CN CNB988101254A patent/CN1192099C/zh not_active Expired - Fee Related
- 1998-08-11 RS YUP-72/00A patent/RS49692B/sr unknown
- 1998-08-11 CA CA002300208A patent/CA2300208C/en not_active Expired - Fee Related
- 1998-08-11 EE EEP200000078A patent/EE04222B1/xx not_active IP Right Cessation
- 1998-08-11 TR TR2000/00404T patent/TR200000404T2/xx unknown
- 1998-08-11 ID IDW20000424A patent/ID25515A/id unknown
- 1998-08-11 PL PL338891A patent/PL191414B1/pl unknown
- 1998-08-11 IL IL13449398A patent/IL134493A/xx not_active IP Right Cessation
- 1998-08-11 BR BRPI9811936-2A patent/BR9811936B1/pt not_active IP Right Cessation
- 1998-08-11 ES ES98940483T patent/ES2186208T3/es not_active Expired - Lifetime
- 1998-08-11 DK DK98940483T patent/DK1003536T3/da active
- 1998-08-11 ME MEP-2000-72A patent/ME00638B/me unknown
- 1998-08-11 SK SK182-2000A patent/SK1822000A3/sk unknown
- 1998-08-11 YU YU7200A patent/YU7200A/sh unknown
- 1998-08-11 JP JP2000509431A patent/JP4387586B2/ja not_active Expired - Lifetime
- 1998-08-11 WO PCT/HU1998/000077 patent/WO1999008694A1/en active IP Right Grant
- 1998-08-11 CZ CZ20000418A patent/CZ298654B6/cs not_active IP Right Cessation
- 1998-08-11 AU AU88802/98A patent/AU754815B2/en not_active Ceased
- 1998-08-11 SK SK186-2000A patent/SK282917B6/sk not_active IP Right Cessation
- 1998-08-11 PT PT98940483T patent/PT1003536E/pt unknown
- 1998-08-11 KR KR1020057013782A patent/KR100544377B1/ko not_active IP Right Cessation
- 1998-08-11 DE DE69809434T patent/DE69809434T2/de not_active Expired - Lifetime
- 1998-08-11 EA EA200000212A patent/EA003090B1/ru not_active IP Right Cessation
- 1998-08-11 AT AT98940483T patent/ATE227580T1/de active
- 1998-08-13 US US09/485,221 patent/US6355474B1/en not_active Expired - Lifetime
- 1998-11-08 UA UA2000020979A patent/UA67747C2/uk unknown
-
2000
- 2000-02-10 NO NO20000675A patent/NO323562B1/no not_active IP Right Cessation
- 2000-03-06 BG BG104220A patent/BG64038B1/bg unknown
-
2001
- 2001-06-05 HK HK01103870A patent/HK1033097A1/xx unknown
-
2009
- 2009-07-21 JP JP2009170505A patent/JP4861458B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-01 JP JP2011168726A patent/JP4886087B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323562B1 (no) | Immunstimulerende og metastasehemmende fermentert torket materiale, fremstilling og anvendelser derav samt kosttilskudd og farmasoytisk produkt. | |
| JP3359642B2 (ja) | 十字花科植物を含む食品の製造方法と十字花科植物のの抽出物 | |
| EP1220680B1 (en) | Echinacea supplement and method of manufacture | |
| KR101409194B1 (ko) | 에쿠올 농도 조절제 | |
| US8709810B2 (en) | Preparation and use of meristematic cells belonging to the Dendrobium phalaenopsis, Ansellia, Polyrrhiza, Vanilla, Cattleya and Vanda genera with high content of phenylpropanoids, hydrosoluble polysaccharides and extensins | |
| MXPA00001557A (en) | Immunostimulatory and metastasis inhibiting fermented vegetal material | |
| JPH11302191A (ja) | ハタケシメジ抽出物を活性成分とする免疫賦活剤及び抗腫瘍剤 | |
| US20010000229A1 (en) | Active oxygen scavenger and cancer chemopreventer from Grifola | |
| RU2735829C1 (ru) | Антимикробное средство на основе лишайника ягеля рода cladonia rangiferina и способ его получения | |
| RU2818479C1 (ru) | Способ получения биопрепарата из вздутоплодника сибирского (Phlojodicarpus sibiricus), обладающего противоопухолевой активностью | |
| JP2009280503A (ja) | クリキュラトリフェネストラータの繭の薬理用途 | |
| WO2024076227A1 (es) | Proceso para la obtención de sustratos con actividad terapéutica a partir del género pleurotus y composiciones que los comprenden | |
| JP2005320307A (ja) | 新規セスキテルペン系化合物、その製造方法及び組成物 | |
| KR20210060233A (ko) | 장 누수 증후군 예방 또는 치료용 약학적 조성물 | |
| JP2003034647A (ja) | 血糖降下作用を有するハタケシメジ抽出物及びその製造方法 | |
| KR20090056171A (ko) | 항염증 효능을 가지는 이질풀 추출물 및 이를 유효성분으로함유하는 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MATE HIDVEGI, HU |
|
| LIS | Published licence |
Free format text: EXCLUSIVE LICENSE Name of requester: BIROPHARMA ELSOE MAGYAR BIOTECHNOLOGIAI KFT, 6413 |
|
| MM1K | Lapsed by not paying the annual fees |